Induction therapy for stage IIIA (N2) lung cancer

Shari L. Meyerson; David H. Harpole

doi:10.1007/978-1-84628-474-8_10

Induction therapy for stage IIIA (N2) lung cancer

Shari L. Meyerson, David H. Harpole

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

2 Scopus citations

Abstract

One of the major goals of the International Staging System for Lung Cancer, first introduced in 1986 and subsequently revised in 1997, was the separation of patients into potentially resectable and unresectable categories. This dividing line was set between stage IIIA and stage IIIB disease with contralateral lymph node metastases or local involvement of unresectable or marginally resectable structures defining the limits of surgical treatment. treatment. The advent of modern cancer therapy with multimodality approaches including surgery, chemotherapy, and radiation therapy has raised significant questions that are still not completely resolved as to the best approach for patients with potentially resectable stage IIIA (N2) disease at presentation.

Original language	English
Title of host publication	Difficult Decisions in Thoracic Surgery
Subtitle of host publication	An Evidence-Based Approach
Pages	88-93
Number of pages	6
DOIs	https://doi.org/10.1007/978-1-84628-474-8_10
State	Published - 2007

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-84628-474-8_10

Cite this

@inbook{876376b284144869ba74c85cc1efd7c6,

title = "Induction therapy for stage IIIA (N2) lung cancer",

abstract = "One of the major goals of the International Staging System for Lung Cancer, first introduced in 1986 and subsequently revised in 1997, was the separation of patients into potentially resectable and unresectable categories. This dividing line was set between stage IIIA and stage IIIB disease with contralateral lymph node metastases or local involvement of unresectable or marginally resectable structures defining the limits of surgical treatment. treatment. The advent of modern cancer therapy with multimodality approaches including surgery, chemotherapy, and radiation therapy has raised significant questions that are still not completely resolved as to the best approach for patients with potentially resectable stage IIIA (N2) disease at presentation.",

author = "Meyerson, \{Shari L.\} and Harpole, \{David H.\}",

year = "2007",

doi = "10.1007/978-1-84628-474-8\_10",

language = "English",

isbn = "1846283841",

pages = "88--93",

booktitle = "Difficult Decisions in Thoracic Surgery",

}

TY - CHAP

T1 - Induction therapy for stage IIIA (N2) lung cancer

AU - Meyerson, Shari L.

AU - Harpole, David H.

PY - 2007

Y1 - 2007

N2 - One of the major goals of the International Staging System for Lung Cancer, first introduced in 1986 and subsequently revised in 1997, was the separation of patients into potentially resectable and unresectable categories. This dividing line was set between stage IIIA and stage IIIB disease with contralateral lymph node metastases or local involvement of unresectable or marginally resectable structures defining the limits of surgical treatment. treatment. The advent of modern cancer therapy with multimodality approaches including surgery, chemotherapy, and radiation therapy has raised significant questions that are still not completely resolved as to the best approach for patients with potentially resectable stage IIIA (N2) disease at presentation.

AB - One of the major goals of the International Staging System for Lung Cancer, first introduced in 1986 and subsequently revised in 1997, was the separation of patients into potentially resectable and unresectable categories. This dividing line was set between stage IIIA and stage IIIB disease with contralateral lymph node metastases or local involvement of unresectable or marginally resectable structures defining the limits of surgical treatment. treatment. The advent of modern cancer therapy with multimodality approaches including surgery, chemotherapy, and radiation therapy has raised significant questions that are still not completely resolved as to the best approach for patients with potentially resectable stage IIIA (N2) disease at presentation.

UR - https://www.scopus.com/pages/publications/43649095949

UR - https://www.scopus.com/inward/citedby.url?scp=43649095949&partnerID=8YFLogxK

U2 - 10.1007/978-1-84628-474-8_10

DO - 10.1007/978-1-84628-474-8_10

M3 - Chapter

AN - SCOPUS:43649095949

SN - 1846283841

SN - 9781846283840

SP - 88

EP - 93

BT - Difficult Decisions in Thoracic Surgery

ER -

Induction therapy for stage IIIA (N2) lung cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this